Cargando…

Glutathione: Pharmacological aspects and implications for clinical use in non-alcoholic fatty liver disease

Glutathione is a tripeptide synthesized at cytosolic level, that exists in cells in a reduced form (thiol-reduced-GSH-) and in an oxidized form (disulfide-oxidized). The antioxidant function of GSH has led to speculation about its therapeutic role in numerous chronic diseases characterized by altere...

Descripción completa

Detalles Bibliográficos
Autores principales:	Santacroce, Giovanni, Gentile, Antonella, Soriano, Simone, Novelli, Andrea, Lenti, Marco Vincenzo, Di Sabatino, Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10075255/ https://www.ncbi.nlm.nih.gov/pubmed/37035339 http://dx.doi.org/10.3389/fmed.2023.1124275

Ejemplares similares

Therapeutic Targeting of Intestinal Fibrosis in Crohn’s Disease
por: Santacroce, Giovanni, et al.
Publicado: (2022)

Liver-spleen axis dysfunction in COVID-19
por: Cococcia, Sara, et al.
Publicado: (2021)

Alcohol? Not for Non-alcoholic Fatty Liver Disease Patients
por: Cainelli, Francesca, et al.
Publicado: (2020)

Liver Fibrosis and MAFLD: From Molecular Aspects to Novel Pharmacological Strategies
por: Qu, Weiyi, et al.
Publicado: (2021)

Hypoxia and Non-alcoholic Fatty Liver Disease
por: Isaza, Stephania C., et al.
Publicado: (2020)

Non-alcoholic Fatty Liver Disease and Alcohol-Related Liver Disease: Two Intertwined Entities
por: Idalsoaga, Francisco, et al.
Publicado: (2020)

Editorial: Liver Fibrosis and MAFLD: From Molecular Aspects to Novel Pharmacological Strategies
por: Sandoval-Rodriguez, Ana, et al.
Publicado: (2022)

Disturbances in Cholesterol Homeostasis and Non-alcoholic Fatty Liver Diseases
por: Malhotra, Pooja, et al.
Publicado: (2020)

Pharmacological Treatment for Non-alcoholic Fatty Liver Disease
por: Francque, Sven, et al.
Publicado: (2019)

Role of mucosal immunity and epithelial–vascular barrier in modulating gut homeostasis
por: Di Sabatino, Antonio, et al.
Publicado: (2023)

Knowing What’s Out There: Awareness of Non-Alcoholic Fatty Liver Disease
por: Ghevariya, Vishal, et al.
Publicado: (2014)

Hepatic Unsaturated Fatty Acids Are Linked to Lower Degree of Fibrosis in Non-alcoholic Fatty Liver Disease
por: Fridén, Michael, et al.
Publicado: (2022)

Translational Aspects of Diet and Non-Alcoholic Fatty Liver Disease
por: Goossens, Nicolas, et al.
Publicado: (2017)

Psychological Biomarkers and Fibrosis: An Innovative Approach to Non-alcoholic Fatty Liver Disease
por: Funuyet-Salas, Jesús, et al.
Publicado: (2020)

Oxidative Stress in Non-alcoholic Fatty Liver Disease. An Updated Mini Review
por: Delli Bovi, Anna Pia, et al.
Publicado: (2021)

Hypoxia-Inducible Factors as Key Players in the Pathogenesis of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis
por: Holzner, Lorenz M. W., et al.
Publicado: (2021)

The Effects of Modest Alcohol Consumption on Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
por: Wongtrakul, Wasit, et al.
Publicado: (2021)

Effect of pemafibrate on liver enzymes and shear wave velocity in non-alcoholic fatty liver disease patients
por: Sugimoto, Ryosuke, et al.
Publicado: (2023)

Liver Fibrosis in Non-alcoholic Fatty Liver Disease: From Liver Biopsy to Non-invasive Biomarkers in Diagnosis and Treatment
por: Heyens, Leen J. M., et al.
Publicado: (2021)

Is Fatty Liver Associated With Depression? A Meta-Analysis and Systematic Review on the Prevalence, Risk Factors, and Outcomes of Depression and Non-alcoholic Fatty Liver Disease
por: Xiao, Jieling, et al.
Publicado: (2021)

Potential Blood DNA Methylation Biomarker Genes for Diagnosis of Liver Fibrosis in Patients With Biopsy-Proven Non-alcoholic Fatty Liver Disease
por: Sun, Qing-Feng, et al.
Publicado: (2022)

Role of Carnitine in Non-alcoholic Fatty Liver Disease and Other Related Diseases: An Update
por: Li, Na, et al.
Publicado: (2021)

Depression in non-alcoholic fatty liver disease is associated with an increased risk of complications and mortality
por: Ng, Cheng Han, et al.
Publicado: (2022)

Case Report: Two Is Not (Always) Better Than One: Pyloric Gland Adenoma of the Gastric Cardia and Concurrent Neuroendocrine Cell Dysplasia Arising From Autoimmune Gastritis
por: Guerini, Camilla, et al.
Publicado: (2022)

Editorial: The broader aspects of non-alcoholic fatty liver disease in children
por: Mandato, Claudia, et al.
Publicado: (2022)

Triple Diagnosis of Attention-Deficit/Hyperactivity Disorder with Co-existing Bipolar and Alcohol Use Disorders: Clinical Aspects and Pharmacological Treatments
por: Weiss, Francesco, et al.
Publicado: (2023)

Current and emerging pharmacological therapy for non-alcoholic fatty liver disease
por: Eshraghian, Ahad
Publicado: (2017)

Non-alcoholic Fatty Liver Disease and Longitudinal Cognitive Changes in Middle-Aged and Elderly Adults
por: Liu, Qi, et al.
Publicado: (2022)

Factors That Predict the Progression of Non-alcoholic Fatty Liver Disease (NAFLD)
por: Parameswaran, Madhangi, et al.
Publicado: (2021)

Study of Endothelial Dysfunction in Patients With Non-alcoholic Fatty Liver Disease
por: Jose, Nijin, et al.
Publicado: (2021)

Non-alcoholic Fatty Liver Disease and Gallstones: A Systematic Review
por: Slouha, Ethan, et al.
Publicado: (2023)

Corrigendum: Diagnostic Delay of Pulmonary Embolism in COVID-19 Patients
por: Melazzini, Federica, et al.
Publicado: (2022)

Diagnostic Delay of Pulmonary Embolism in COVID-19 Patients
por: Melazzini, Federica, et al.
Publicado: (2021)

Editorial: Dissecting the immunological, pathological, and clinical aspects of autoimmune gastritis and its neoplastic complications
por: Lenti, Marco Vincenzo, et al.
Publicado: (2022)

Relevant Aspects of Nutritional and Dietary Interventions in Non-Alcoholic Fatty Liver Disease
por: Hernandez-Rodas, Maria Catalina, et al.
Publicado: (2015)

Assessment of Genetic Aspects of Non-alcoholic Fatty Liver and Premature Cardiovascular Events
por: Saki, Sara, et al.
Publicado: (2020)

CML/RAGE Signal Bridges a Common Pathogenesis Between Atherosclerosis and Non-alcoholic Fatty Liver
por: Pang, Qiwen, et al.
Publicado: (2020)

Oral and Gut Microbial Dysbiosis and Non-alcoholic Fatty Liver Disease: The Central Role of Porphyromonas gingivalis
por: Wang, Ting, et al.
Publicado: (2022)

Impact of COVID‐19 in immunosuppressive drug‐naïve autoimmune disorders: Autoimmune gastritis, celiac disease, type 1 diabetes, and autoimmune thyroid disease
por: Santacroce, Giovanni, et al.
Publicado: (2022)

Anthropometric Measurements and Lifestyle Characteristics of Individuals with Non-alcoholic Fatty Liver Disease
por: Tahir, Faryal, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_87e6mhd6mopjunpnc1hh0mqmli